From COVID-19 to the seasonal flu and RSV, vaccinations for respiratory viruses are typically delivered via intramuscular injection, which generates antibodies in the bloodstream. But the first line ...

In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based drugs and vaccines are designed. Developed through a collaboration between ...

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called RiboNN predicts which sequences will be most efficiently produced and ...

Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 ...